These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 18516763)

  • 1. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTI-2040. Lorus Therapeutics.
    Orr RM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
    Mills DA; Fekrazad HM; Verschraegen CF
    Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
    LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
    Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.
    Lacasse EC; Kandimalla ER; Winocour P; Sullivan T; Agrawal S; Gillard JW; Durkin J
    Ann N Y Acad Sci; 2005 Nov; 1058():215-34. PubMed ID: 16394139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: AVI-4126, AVI BioPharma.
    Stephens AC
    Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
    Hammond SM; Wood MJ
    Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Cummings J; Ward TH; LaCasse E; Lefebvre C; St-Jean M; Durkin J; Ranson M; Dive C
    Br J Cancer; 2005 Feb; 92(3):532-8. PubMed ID: 15685240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
    Choueiri TK
    Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
    Vallières L
    IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156.
    LaCasse EC
    Cancer Lett; 2013 May; 332(2):215-24. PubMed ID: 22776562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GTI-2501. Lorus Therapeutics.
    Tu GC; Tu X
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1467-70. PubMed ID: 11890367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.